ENGOT-ov60/GOG3052/RAMP 201: A Phase 2 Study of VS-6766 (dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
Molecular Cancer Therapeutics（2021）
Key words
Cancer Therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined